의약품안전나라 > HOMEPAGE

본문바로가기
주메뉴바로가기

국가
검색어
제제

※ 출처: ClinicalTrials.gov

총 14,937건

해외임상승인현황 정보 :: 순번, 임상시험 제목, 적응증, 연구설계, 의뢰자/실시기관, 임상단계, NCT No, 개시일자
순번	임상시험 제목	적응증	연구설계	의뢰자/실시기관	임상단계	NCT No	개시일자
1	Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors	Solid Tumor\|Solid Tumor, Adult	Biological: Sargramostim\|Biological: Ipilimumab-containing therapy	Partner Therapeutics, Inc.	Phase 2	NCT05284214	2024-01-01
2	GDNF Gene Therapy for Multiple System Atrophy	Multiple System Atrophy	Biological: AAV2-GDNF gene therapy\|Procedure: Sham (Placebo) Surgery	Brain Neurotherapy Bio, Inc.	Phase 1	NCT04680065	2023-10-03
3	The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer	Limited Stage Small Cell Lung Cancer	Combination Product: chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy	Shanghai Pulmonary Hospital, Shanghai, China\|Jiangsu HengRui Medicine Co., Ltd.	Phase 3	NCT05496166	2023-08-01
4	A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma	Multiple Myeloma	Drug: Daratumumab\|Drug: Bortezomib\|Drug: Lenalidomide\|Drug: Dexamethasone\|Drug: Cilta-cel\|Drug: Cyclophosphamide\|Drug: Fludarabine	European Myeloma Network\|Janssen Research & Development, LLC	Phase 3	NCT05257083	2023-08-01
5	A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma	Multiple Myeloma	Drug: Daratumumab\|Drug: Bortezomib\|Drug: Lenalidomide\|Drug: Dexamethasone\|Drug: Cilta-cel\|Drug: Cyclophosphamide\|Drug: Fludarabine	European Myeloma Network\|Janssen Research & Development, LLC	Phase 3	NCT05257083	2023-08-01
6	A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma	Multiple Myeloma	Drug: Daratumumab\|Drug: Bortezomib\|Drug: Lenalidomide\|Drug: Dexamethasone\|Drug: Cilta-cel\|Drug: Cyclophosphamide\|Drug: Fludarabine	European Myeloma Network\|Janssen Research & Development, LLC	Phase 3	NCT05257083	2023-08-01
7	A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma	Multiple Myeloma	Drug: Daratumumab\|Drug: Bortezomib\|Drug: Lenalidomide\|Drug: Dexamethasone\|Drug: Cilta-cel\|Drug: Cyclophosphamide\|Drug: Fludarabine	European Myeloma Network\|Janssen Research & Development, LLC	Phase 3	NCT05257083	2023-08-01
8	Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies	T-Cell Non-Hodgkin Lymphoma\|Acute Myeloid Leukemia\|Angioimmunoblastic T-cell Lymphoma\|Enteropathy-Associated T-Cell Lymphoma\|Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma\|Peripheral T Cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Adult T Cell Leukemia\|Adult T Cell Lymphoma\|T Cell Prolymphocytic Leukemia\|Extranodal NK/T-cell Lymphoma\|Transformed Mycosis Fungoides\|Sezary Syndrome\|Primary Cutaneous Gamma-Delta T-Cell Lymphoma\|Hepatosplenic T-cell Lymphoma	Biological: WU-CART-007	Washington University School of Medicine\|Wugen, Inc.	Phase 1	NCT05377827	2023-07-31
9	A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients	Ovarian Cancer Stage IV\|Ovarian Cancer Stage III\|Ovarian Cancer Stage 3	Biological: NY-ESO-1 Peptide vaccine\|Drug: Nivolumab	Georgetown University\|United States Department of Defense\|Bristol-Myers Squibb	Phase 2	NCT05479045	2023-07-01
10	A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)	Acute Myeloid Leukemia	Biological: WU-NK-101	Wugen, Inc.	Phase 1	NCT05470140	2023-07-01

1 2 3 4 5 6 7 8 9 10